Showing 1199 results
- Key Release /Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone…
- Key Release /One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD…
- Key Release /SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1],[2…
- Media Release /Driving growth through cutting edge pipeline with 15 in-market blockbusters and more than 25 potential blockbusters in development, including 10+ planned launches by 2021 Strong progress on…
- Media Release /New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled…
- Media Release /Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary…
- Media Release /Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya® (fingolimod) 0.5mg had significantly fewer relapses than patients…
- Media Release /Sandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China's…
- Key Release /Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline…
- Media Release /Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive…
Pagination
- ‹ Previous page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- …
- 120
- › Next page